Dainippon offers $200mm up front and over $2bn in earn-outs to buy Boston Biomedical
Executive Summary
Less than a year after striking up their first collaboration together, Japanese drug company Dainippon Sumitomo Pharma Co. Ltd. (DSP) has decided to acquire private partner Boston Biomedical Inc. (developing oncology therapies that target cancer stem cells). DSP will pay $200mm up front and up to $2.43bn in earn-outs ($540mm based on development of Boston Biomedical’s candidates and up to $1.89bn in various sales milestones, with the maximum paid when $4bn in net sales are achieved in any fiscal year.)
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash for Equity
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice